Konstantinos Pantos, Konstantinos Sfakianoudis, Sokratis Grigoriadis, Evangelos Maziotis, Petroula Tsioulou, Anna Rapani, Polina Giannelou, Anastasios Atzampos, Sevasti Koulouraki, Michael Koutsilieris, Nikolaos Vlahos, George Mastorakos and Mara Simopoulou

Abstract: Background and Objectives: Clinicians are called to overcome age-related challenges in decision making during In Vitro Fertilization (IVF) treatment. The aim of this study was to investigate the possible impact of a single calendar year defference among patients aged 34, 35 and 36 on IVF outcomes. Materials and Methods: Medical records between 2008 and 2019 were analyzed retrospectively. The study group consisted of women diagnosed with tubal factor infertility. Sample size was divided in three categories at 34, 35 and 36 years of age. Embryo transfer including two blastocysts was performed for every patient. Comparisons were performed regarding hormonal profile, response to stimulation, quality of transferred embryos, positive hCG test and clinical pregnancy rate. Results: A total of 706 women were eligible to participate. Two-hundred and forty-eight women were 34, 226 were 35 while the remaining 232 were 36 years old. Regarding the hormonal profile, the number of accumulated oocytes and the quality of embryos transferred, no statistically significant dfference was documented between the three age groups. Women aged 34 and 35 years old indicated a significantly increased positive hCG rate in comparison to women aged 36 years old (p-value = 0.009, p-value = 0.023, respectively). Women aged 34 and 35 years old presented with a higher clinical pregnancy rate in comparison to those aged 36 years old (p-value = 0.04, p-value = 0.05, respectively). Conclusion: A calendar year difference between patients undergoing IVF treatment at 34 or 35 years of age does not appear to exert any influence regarding outcome. When treatment involves patients above the age of 35, then a single calendar year may exert considerable impact on IVF outcome. This observation indicates that age 35 may serve as a valid cut-off point regarding IVF outcome.

Full artcle

Male fertility evaluation following empirical treatment with tamoxiphen citrate and testosterone undecanoate, in men with idiopathic oligo- astheno- terato- zoospermia.

Abstract

Objective: In this retrospective analysis, we aimed to evaluate and compare pre- and post-treatment sperm parameters in men with idiopathic subfertility subscribed with a combination of tamoxiphen citrate and testosterone undecanoate, according to both 1999 and 2010 World Health Organization (WHO) criteria. Materials and Methods: The study included 28 participants, comprising of male patients with idiopathic subfertility and a mean age of 36.6 years. Results: According to the 1999 WHO criteria, the sum of the participants were classified as subfertile and none of the patients demonstrated the desired improvement to overcome the designated threshold values following treatment. According to the updated 2010 criteria, 89.3% of the cohort was classified as subfertile, demonstrating an improvement of 14.3% following treatment, while the remaining 10.7% of the participants classified as fertile, exhibited a significant improvement in their sperm parameters (120%). Overall, the empirical treatment resulted in the improvement in the sum of sperm parameter values in 58.9% of the cohort recruited. Conclusion: Our results provide preliminary evidence supporting the hypothesis that empirical treatment demonstrated encouraging results in men with idiopathic infertility and borderline sperm parameters. Further research is required with the recruitment of an appropriate sized cohort and direct comparisons to be performed with alternative pharmaceutical treatments.

Sofia Vappa, Christalena Sophocleous, Konstantinos Nikas, Georgios Mastorakos, Emmanouel  Kanavakis, Christina Kanaka-Gantenbein

Current literature suggests an important role of both endocrine disruptors and genetic factors in the occurrence of cryptorchidism. The aim of the study is to investigate the impact of variants in INSL3 and HOXD13 genes in the pathogenesis of isolated cryptorchidism in Greece. Forty-three boys with isolated cryptorchidism and 50 healthy non-cryptorchidic boys (control group) were enrolled. Genomic DNA was extracted from peripheral blood leukocytes and genetic analysis was conducted using PCR and direct sequencing of Insl3 and HOXD13 gene regions. Two apparently novel variants, the * -109 T>A of the Insl3 5’ UTR and the *528_529inv of the HOXD13 3’ UTR were disclosed in two unrelated patients. None of these variants was revealed in the control group (p=0.32304). Conversely, multiple previously described polymorphisms of both genes (Insl3:  c.27G>A, c.126A>G and c.178A>G/ HOXD13: c.*311C> T, c.*360A> T and c.*359_*360insT) were detected in both the cryptorchidic patients and the control group with no statistically significant difference between groups. “In silico” analysis for the two as yet unreported findings indicated possible alterations  of the  cDNA sequences but with no comprehensible impact on the coding procedure. A combination of polymorphic alleles in these two genes was observed in both patients and controls without any statistically significant difference between groups (p=0.30873). Neither the presence of specific polymorphisms in the INSL3 and HOXD13 genes, nor their combination could account for the pathogenesis of isolated cryptorchidism. The effect of endocrine disruptors or variations in non-examined genes in the pathogenesis of cryptorchidism, as well as the better delineation of the role of the new detected variants should be further investigated in larger populations.

Full poster

N Nikolaou, M Nasiri, LL Gathercole, S Parajes, N Krone, G Valsamakis, G Mastorakos3, JW Tomlinson

Increased mRNA expression of FAS, ACC1 and ACC2 as well decreased CPT1 mRNA expression contribute to the increase in de novo lipogenesis that is observed
with testosterone and DHT treatment. Surprisingly, we also observed that AR overexpression alone, in the absence of ligand, also regulates hepatic lipid metabolism
by increasing both the expression of key components of the lipogenic pathway (FAS, ACC1, ACC2) and functional lipid accumulation. We have shown that
glucocorticoids decrease de novo lipogenesis in a dose-dependent manner and manipulation of 5αR2 activity can regulate lipogenesis in human hepatocytes in vitro.
These data demonstrate that androgens and glucocorticoids are able to stimulate lipid accumulation in human hepatocytes and this may be crucial in understanding
the association between PCOS and NAFLD.

Full Poster

NAME Joeri Vermeulen
ADDRESS Laarbeeklaan 121, 1090 Brussels, Belgium
TEL. +32 475 55 74 68
E-MAIL joeri.vermeulen@ehb.be
DATE OF BIRTH Herk de Stad, Belgium on 08/12/1967
LANGUAGES F/E/D
WEBSITE https://researchportal.vub.be/en/persons/joeri-vermeulen
ORCID      0000-0002-9568-3208
H-index    8

Continue reading →

Όνομα: ΑΙΜΙΛΙΑ ΜΑΝΤΖΟΥ
Διεύθυνση κατοικίας: ΚΑΡΒΕΛΑ 23, 15342 ΑΓΙΑ ΠΑΡΑΣΚΕΥΗ
Ημερομηνία γεννήσεως: 18. 03.71
Tόπος γεννήσεως: ΑΘΗΝΑ
Ηλεκτρονικό Ταχυδρομείο: amantzou@med.uoa.gr
Διεύθυνση εργασίας: Εργαστήριο Κλινικής και Μεταφραστικής Έρευνας στην Ενδοκρινολογία Χωρέμειο Ερευνητικό Εργαστήριο της Α’ Παιδιατρικής Κλινικής του
Νοσοκομείου Παίδων «Η Αγία Σοφία»

Continue reading →

Ο Γιώργος Πιερράκος είναι Καθηγητής μέλος ΔΕΠ στο Τμήμα Διοίκησης Επιχειρήσεων και μέλος του Τομέα Κοινωνικής Πολιτικής στο Πανεπιστήμιο Δυτικής Αττικής, στο αντικείμενο της Οργάνωσης και Διοίκησης Υπηρεσιών Πρωτοβάθμιας Φροντίδας Υγείας.
Είναι κάτοχος διδακτορικού διπλώματος από τη Σχολή Πολιτικών Επιστημών και Δημόσιας Διοίκησης του Εθνικού και Καποδιστριακού Πανεπιστημίου Αθηνών (ΕΚΠΑ).

Continue reading →

Απόφοιτος της Ιατρικής Σχολής του Εθνικού και Καποδιστριακού Πανεπιστημίου Αθηνών με βαθμό ‘Λίαν καλώς’ 7.45
17.05.2004 – 04.09.2005 Γενικό Νοσοκομείο Κιλκίς και Κέντρο Υγείας Δροσάτου, στο πλαίσιο εκπλήρωσης της υποχρεωτικής υπηρεσίας υπαίθρου.
17.10.2005 – 16.07.2006 Α’ Χειρουργική Κλινική 1^ου Νοσοκομείου ΙΚΑ Αθηνών, σε θέση ειδικευόμενου ιατρού στη Γενική Χειρουργική.
27.12.2006 – 08.04.2008 Ιατρός – Αξιωματικός Υγειονομικού με βαθμό Σημαιοφόρου Ιατρού, σε Αρματαγωγό Πλοίο του Στόλου του Πολεμικού Ναυτικού και ακολούθως στο Αγγειοχειρουργικό Τμήμα του Ναυτικού Νοσοκομείου Αθηνών.
01.09.2008 – 20.08.2010 Β’ Γυναικολογική Κλινική Αντικαρκινικού – Ογκολογικού Νοσοκομείου Αθηνών ‘Ο Άγιος Σάββας’, σε θέση ειδικευόμενου ιατρού στη Μαιευτική –Γυναικολογία.

Continue reading →

Ο κ. Πανοσκάλτσης σπούδασε στην Ιατρική Σχολή του Πανεπιστημίου Αθηνών. Αφού ολοκλήρωσε την στρατιωτική θητεία στο 216 Τάγμα Υγειονομικού στο Διδυμότειχο Έβρου, την υπηρεσία ως Αγροτικός Ιατρός και την προαπαιτούμενη εκπαίδευση στη Γενική Χειρουργική, έγινε δεκτός για εκπαίδευση στη Μαιευτική και Γυναικολογία στη Μεγάλη Βρετανία, όπου εργάστηκε ως ειδικευόμενος και ειδικός ιατρός για 11 έτη.

Continue reading →

Dr. Barber has been employed as an Associate Professor and Honorary Consultant Endocrinologist at University of Warwick and University Hospitals Coventry and Warwickshire (UHCW) since 2010.

Continue reading →